Clinical impact of tocilizumab in treatment of severe COVID-19 patients: Retrospective cohort study.
Abstract
Introduction:
Tocilizumab (TCZ) is an interleukin-6 receptor blocker proposed to treat severe or critical COVID-19 patients. This study aims to evaluate the clinical effects of TCZ administration in hospitalized patients with severe COVID-19. Additionally, the study investigates the most common adverse and infectious events associated with the use of TCZ.
Materials and methods:
Analytical, observational case-control study matched by age, sex, and comorbidities of adult patients with severe COVID-19, hospitalized between December 2020 and March 2021. Inclusion criteria: requirement for oxygen provision greater than or equal to 5 l/min to achieve saturation >93% and one of the following: stroke, myocardial infarction, BMI >30, chronic kidney disease, age >60 years, D-dimer >1000 ng/ml, or quantitative C-reactive protein >75 mg/l. Outcomes evaluated: all-cause mortality, transfer to critical care unit (CCU), and mechanical ventilatory assistance (MVA) requirement.
Results
The study included 320 patients, out of which 110 patients received TCZ in addition to corticosteroids (cases), while 210 patients were only exposed to corticosteroids (controls). The mortality rate was 29% in the cases group, compared to 44% in the control group (p=0.0081). Similarly, 48% of the cases were transferred to CCU, while 81% of the control group were transferred (p=0.0081). The requirement for mechanical ventilation (MVA) was 24% in the cases group and 56% in the control group (p=0.0001).
Conclusion
Patients treated with TCZ had a lower proportion of CCU use, MVA, and mortality compared to similar patients who did not receive it. These results are consistent with the current evidence.
Downloads
References
2- REMAP-CAP Investigators; Gordon, A. C., Mouncey, P. R., Al-Beidh, F., et al. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 384(16), 1491-1502. doi:10.1056/NEJMoa2100433.
3- RECOVERY Collaborative Group. (2021, May 1). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomized, controlled, open-label, platform trial. The Lancet, 397(10285), 1637-1645. https://doi.org/10.1016/S0140-6736(21)00676-0
4- The RECOVERY Collaborative Group*. (2021). Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 384(8), 693-704. doi:10.1056/NEJMoa2021436.
5- Ragusa, M. A., Tortosa, F., Carrasco, G., Montero, G., Haluska, P., Lamfre, L., & Izcovich, A. (2021). Guía de práctica clínica: Tocilizumab para pacientes con COVID-19 grave o crítica. Medicina (Buenos Aires), 81(6), 1015.
6- Ministerio de Salud, Secretaría de Políticas, Regulación e Institutos. (2015). Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). Recuperado de https://boletin.anmat.gob.ar/febrero_2011/Dispo_1071-11.pdf. Consultado en octubre de 2023.
7- Hermine, O., Mariette, X., Tharaux, P. L., Resche-Rigon, M., Porcher, R., Ravaud, P., ... & Mariette, X. (2020). Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Internal Medicine, 181(1), 32-40. doi:10.1001/jamainternmed.2020.6820.
8- Veiga, V. C., Prats, J., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., & Azevedo, L. C. P. (2021). Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, 372, n84. doi:10.1136/bmj.n84.
9- Boppana, T. K., Mittal, S., Madan, K., Mohan, A., Hadda, V., & Guleria, R. (2022). Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Monaldi Arch Chest Dis, 92(4). doi:10.4081/monaldi.2022.2136
10- Albuquerque, A. M., Eckert, I., Tramujas, L., Butler-Laporte, G., McDonald, E. G., Brophy, J. M., & Lee, T. C. (2023). Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: A systematic review and meta-analysis. Review Clin Microbiol Infect, 29(1), 13-21. doi:10.1016/j.cmi.2022.07.008
11 -Meyerowitz, E. A., Sen, P., Schoenfeld, S. R., Neilan, T. G., Frigault, M. J., Stone, J. H., Kim, A. Y., & Mansour, M. K. (2021, June 15). Immunomodulation as treatment for severe Coronavirus Disease 2019: A systematic review of current modalities and future directions. Clinical Infectious Diseases, 72(12), e1130-e1143. doi:10.1093/cid/ciaa1759
12- Guirao, J. J., Cabrera, C. M., Jiménez, N., Rincón, L., & Urra, J. M. (2020, December). High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. Molecular Immunology, 128, 64-68. doi:10.1016/j.molimm.2020.10.006
